Evergreen Theragnostics is a US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO). The project involves the creation of a radiopharmaceutical production plant in New Jersey, in order to benefit from the growth opportunity expected in the sector.
Location: United States, New Jersey, Jersey City
Total raised: $41M
Investors 2
| Date | Name | Website |
| - | Club degli... | clubdeglin... |
| - | NovaCapita... | novacapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.04.2024 | - | $26M | - |
| 15.03.2023 | Series B | $15M | - |
Mentions in press and media 13
| Date | Title | Description |
| 21.05.2024 | Evergreen Theragnostics announces licensing of EVG321 from Medical University of Innsbruck and enters clinical development of Radioligand Therapies in small cell lung cancer | SPRINGFIELD, N.J., May 21, 2024 /PRNewswire/ -- Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced that they have entered into a collaboration and licensing-agreement with the Medical University of ... |
| 18.04.2024 | Evergreen Theragnostics Secures $26M to Drive Radiopharmaceutical Innovation | Evergreen Theragnostics, a cutting-edge radiopharmaceutical company based in Springfield, NJ, has successfully completed a $26M capital raise, with support from Petrichor and LIFTT. This funding will propel the company's groundbreaking rese... |
| 16.04.2024 | Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Servic... | SPRINGFIELD, N.J., April 16, 2024 /PRNewswire/ -- Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced the successful completion of a $26M capital raise supported both by existing shareholders and new... |
| 16.04.2024 | Evergreen Theragnostics Completes $26M Funding | Evergreen Theragnostics, a Springfield, NJ-based clinical-stage radiopharmaceutical company, raised $26M in funding. Backers included Petrichor and LIFTT. The company intends to use the funds to expand operations and its R&D sector. Led... |
| 15.03.2023 | Evergreen Theragnostics Closes $15M Series B Funding | Evergreen Theragnostics, a Springfield, NJ-based clinical stage contract development and manufacturing organization (CDMO), raised $15M in Series B funding. The backers were nor disclosed. The company intends to use the funds to prepare for... |
| 13.03.2023 | Evergreen Theragnostics Nets $15M Series B | SPRINGFIELD, NJ, Evergreen Theragnostics, a clinical stage contract development and manufacturing organization, announced the completion of a $15M Series B. >> Click here for more funding data on Evergreen Theragnostics >> T... |
| 30.09.2021 | Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement for US Clinical trials | SYDNEY, Sept. 30, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, and... |
| 15.07.2021 | Evergreen Theragnostics Expands Alpha Radiopharmaceutical Production Capabilities | |
| 16.11.2020 | Why contract development and manufacturing for radiopharma may be a smart move | One of the fastest-growing segments in the life sciences industry is that of radiopharmaceuticals, or what some call nuclear medicine. The global market for radiopharmaceuticals was valued at $6.1 billion in 2019 and is estimated to reach $... |
| 22.06.2020 | Evergreen Theragnostics Completes $19 Million Series A | Evergreen Theragnostics, Inc., a radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced that it has raised $19M in a Series A financing round. The investment was made by private investors in common s... |
Show more